ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 6,364 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $76.94, for a total value of $489,646.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Pendarvis also recently made the following trade(s):

  • On Tuesday, September 5th, David Pendarvis sold 6,364 shares of ResMed stock. The stock was sold at an average price of $77.21, for a total value of $491,364.44.
  • On Thursday, August 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The stock was sold at an average price of $72.10, for a total value of $458,844.40.

Shares of ResMed Inc. (RMD) traded up 0.30% during midday trading on Thursday, reaching $77.50. The company’s stock had a trading volume of 123,000 shares. The stock’s 50 day moving average price is $76.90 and its 200 day moving average price is $73.91. The firm has a market cap of $11.02 billion, a price-to-earnings ratio of 32.29 and a beta of 0.77. ResMed Inc. has a one year low of $56.59 and a one year high of $81.87.

ResMed (NYSE:RMD) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.02. The company had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 earnings per share. Analysts predict that ResMed Inc. will post $3.05 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th were given a $0.35 dividend. This is a positive change from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date was Tuesday, August 15th. This represents a $1.40 dividend on an annualized basis and a yield of 1.81%. ResMed’s payout ratio is presently 58.09%.

COPYRIGHT VIOLATION WARNING: “Insider Selling: ResMed Inc. (RMD) Insider Sells 6,364 Shares of Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/05/insider-selling-resmed-inc-rmd-insider-sells-6364-shares-of-stock-2.html.

A number of research firms recently commented on RMD. Credit Suisse Group downgraded ResMed from an “outperform” rating to a “neutral” rating in a research report on Tuesday, August 8th. Zacks Investment Research downgraded ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. BMO Capital Markets boosted their target price on ResMed from $61.00 to $70.00 and gave the stock a “market perform” rating in a research report on Wednesday, August 2nd. Citigroup Inc. upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. Finally, BidaskClub downgraded ResMed from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $68.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in RMD. BlackRock Inc. raised its position in ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after purchasing an additional 13,094,421 shares during the period. FMR LLC raised its position in ResMed by 38.2% in the second quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after purchasing an additional 1,531,772 shares during the period. Koch Industries Inc. raised its position in ResMed by 17,065.2% in the second quarter. Koch Industries Inc. now owns 985,796 shares of the medical equipment provider’s stock valued at $973,000 after purchasing an additional 980,053 shares during the period. Morgan Stanley raised its position in ResMed by 69.1% in the first quarter. Morgan Stanley now owns 1,344,234 shares of the medical equipment provider’s stock valued at $96,744,000 after purchasing an additional 549,279 shares during the period. Finally, Vanguard Group Inc. raised its position in ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after purchasing an additional 508,392 shares during the period. 60.10% of the stock is currently owned by institutional investors.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.